pharminent

• News

FDA Approves Revolution Medicines’ Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer

pharminent August 26, 2026

• Clinical Data

Spyre deprioritises arthritis drug after Phase 2 results

pharminent August 26, 2026

• M&A / Deals

Metsera backers establish new biotech armed with China-licensed immunology asset

pharminent August 26, 2026

• Regulatory

Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2

pharminent August 26, 2026

• Regulatory

Jazz secures FDA approval for Ziihera in advanced HER2+ GEA

pharminent August 26, 2026

• M&A / Deals

McKesson to acquire Precision Medicine Group for $2.25bn

pharminent August 26, 2026

• News

FDA Approves J&J’s Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease

pharminent August 25, 2026

• Regulatory

Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test

pharminent August 25, 2026

• M&A / Deals

China’s Haisco forms immunology biotech with up to $1.5B from American VCs

pharminent August 25, 2026

• Regulatory

Expanded US Imaavy approval first ever for wAIHA

pharminent August 25, 2026

• Pipeline

Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

pharminent August 25, 2026

• Regulatory

FDA greenlights Roche’s biomarker blood test for Alzheimer’s

pharminent August 25, 2026

• Regulatory

FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial

pharminent August 25, 2026

• News

Genentech Licenses Hanmi’s Muscle-Sparing Obesity Drug in Deal Worth Up to $2.3 Billion

pharminent August 24, 2026

• Regulatory

Capricor’s Duchenne therapy has new life after FDA grants 3-month extension

pharminent August 24, 2026

• M&A / Deals

Roche commits to lean-mass preservation with Hanmi obesity deal

pharminent August 24, 2026

• Regulatory

Johnson & Johnson’s multiple myeloma treatment secures EC approval

pharminent August 24, 2026

• Regulatory

UK MHRA authorises orforglipron private prescription

pharminent August 24, 2026

• News

Johnson & Johnson Wins EU Approval for Tecvayli-Daratumumab in Second-Line Myeloma

pharminent August 21, 2026

• Clinical Data

Novo Nordisk starts trialing lower maintenance doses of oral Wegovy

pharminent August 21, 2026

• Market Access

How cost and perception could reshape the GLP-1 market

pharminent August 21, 2026

• Manufacturing

Roche commits $750m to double Oregon-based US manufacturing capacity

pharminent August 21, 2026

• News

Regeneron’s Pasatru Wins Full FDA Approval for Ultra-Rare ‘Stone Man Disease’

pharminent August 20, 2026

• Clinical Data

Cancer vaccine win restores Wall Street’s faith in Moderna

pharminent August 20, 2026

• Gene Therapy

Ultragenyx, after setbacks, nabs first gene therapy approval

pharminent August 20, 2026

• Regulatory

Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa

pharminent August 20, 2026

• Regulatory

Regeneron wins FDA approval to challenge Ipsen for rare bone disease market

pharminent August 20, 2026

• Clinical Data

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

pharminent August 20, 2026

• Regulatory

FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy

pharminent August 20, 2026

• News

Moderna and Merck’s Personalized Melanoma Vaccine Scores Historic Phase 3 Win

pharminent August 19, 2026

• Regulatory

Trump nominates policy aide Overton to lead FDA

pharminent August 19, 2026

• M&A / Deals

BioMarin spends up to $490m for Alesta’s bone disease candidate

pharminent August 19, 2026

• News

Amylyx’s Avexitide Succeeds in Phase 3 Pivotal Study for Post-Bariatric Hypoglycemia

pharminent August 18, 2026

• News

AstraZeneca Claims Dual Lung Cancer Phase 3 Wins, but Bispecific Failure Steals the Headline

pharminent August 17, 2026

• M&A / Deals

J&J hands lymphoma bispecific CAR T back to AbelZeta

pharminent August 17, 2026

• M&A / Deals

Novo Nordisk and AWS form AI partnership to speed drug discovery

pharminent August 17, 2026

• M&A / Deals

Sandoz targets industry patent void with $322m Henlius deal

pharminent August 17, 2026

• Regulatory

Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval

pharminent August 17, 2026

• News

BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple Myeloma

pharminent August 14, 2026

• Regulatory

BMS bags first approval for myeloma CELMoD Zenbexus

pharminent August 14, 2026